Novartis Reports Q3 2026 Growth Driven by Priority Brands Amid Generic Competition
Novartis (NVS) reported third-quarter 2026 net sales of $14.5 billion, representing a 4% increase in constant currency. The growth was primarily driven by strong performance in priority brands such as Kisqali, Scemblix, and Leqvio, which helped offset significant generic erosion in legacy products like Entresto. Core operating income rose 10% to $6.0 billion, supported by margin expansion and productivity initiatives. Despite the revenue growth, the company faced setbacks including a $1.9 billion partial impairment charge for the del-desiran asset following unsuccessful Phase 3 clinical trials. Additionally, free cash flow declined 18% year-over-year to $5.1 billion. However, management raised its full-year 2026 core operating income guidance from a projected low single-digit decline to an expectation of being in line with or growing at a low single-digit rate.
Tickers: $NVS
Topics: earnings report financial guidance pharmaceutical sales revenue growth
Read the full article at Motley Fool
Part of the story Novartis Raises 2026 Core Operating Income Guidance Following Sales Growth (7 articles)